Patients w/ infections, HTN, DM, osteoporosis, peptic ulcer, glaucoma or cataracts or w/ a family history of diabetes or glaucoma, or w/ any other condition where the use of glucocorticoids may have unwanted effects. Gradually reduce dose when treatment is to be discontinued. May result in lower systemic steroid levels than conventional oral glucocorticoid therapy. Transfer from other steroid therapy may result in symptoms relating to the change in systemic steroid levels. Occasional dizziness or tiredness may occur. May reduce immune response to vaccines. Avoid concomitant administration w/ ketoconazole or other potent CYP3A4 inhibitors. Contains lecithin. Rare hereditary problems eg, galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Adrenocortical suppression; increased susceptibility to infections; suppression of the HPA axis & reduced stress response; more serious course of chicken pox & measles; systemic effects of steroids particularly when prescribed at high doses & for prolonged periods. Patients w/ current or previous history of severe affective disorders in the patient or any 1st degree relatives. Replacement of high systemic effect corticosteroid treatment sometimes unmasks allergies eg, rhinitis & eczema. Reduced liver function may affect the elimination of glucocorticoids including budesonide, causing higher systemic exposure. Be aware of possible systemic side effects. Potential systemic effects include glaucoma. Hepatic & renal impairment. Pregnancy & lactation. Childn 0-18 yr. Elderly.